The STEP trials, which tracked semaglutide use over 68 weeks with ongoing monitoring, demonstrated stable efficacy and tolerability without serious cumulative adverse effects
Other companion solution providers should monitor the adoption of GLP-1 companion solutions closely, learn and adopt their offerings
No randomized controlled trial has isolated the additive effect of levocarnitine when given alongside tirzepatide
Curti BD, Richards JM, Hallmeyer S, Faries MB, Andtbacka RHI, Daniels GA, et al
Taken as a whole, it appears that changes in overall patient satisfaction may be limited to transitioning away from twice daily GLP-1 RA treatment to a longer dosing-interval GLP-1 RA therapy
Watch Now In this weeks episode of Be HEALTHistic, we bring you an encore presentation of a recent Facebook Live event with Drs